Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kartos Therapeutics currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner working within 1 distinct art unit. The presence of the art unit for the 1 pending office action indicates that the current prosecution is focused within a single administrative group. Practitioners should note that all current interactions with the USPTO are localized to this point of contact.
The busiest examiner for the portfolio is MCDOWELL, BRIAN E, who is responsible for 1 pending office action. Because there is only 1 distinct examiner involved, the entire pending workload rests with MCDOWELL, BRIAN E. This lack of examiner diversity means that the outcome of the prosecution depends on the requirements of the examiner. For a company in the Biotechnology & Pharmaceuticals sector, this exposure requires a precise understanding of the 1 distinct art unit standards.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690569 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION | MCDOWELL, BRIAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690569 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION | MCDOWELL, BRIAN E | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690569 | METHODS OF TREATING CANCER DEPENDENT ON MYC GENE EXPRESSSION | MCDOWELL, BRIAN E | 1624 | §103§112Other | Non-Final OA | — | Pending | Mar 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKartos Therapeutics has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brian E Mcdowell has the most, with 1 of Kartos Therapeutics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
